💚 Health & Wellness
Today's top 4 stories, curated by Daily Direct.
The Supreme Court has ruled against bans on conversion therapy, a decision with significant implications for LGBTQ+ youth protections across the country. The ruling limits the ability of states and localities to restrict the widely discredited practice. Health advocates warn the decision could expose vulnerable minors to psychological harm.
Read article →
Eli Lilly's oral obesity pill has cleared FDA approval, marking a significant milestone in the rapidly expanding weight-loss drug market. The green light puts Lilly on a direct collision course with Novo Nordisk, whose own pill-form Wegovy is vying for the same patients. With both pharma giants now fielding oral options, the competition to dominate the blockbuster obesity sector is poised to intensify sharply.
Read article →The NHS will extend access to semaglutide (Wegovy) to 1.2 million people in England who are overweight — not necessarily obese — but face elevated cardiovascular risk. The move marks a significant expansion of the drug's approved use beyond obesity and diabetes treatment. It signals a shift toward using GLP-1 drugs as a preventive tool against heart attacks and strokes, potentially easing pressure on cardiac care services.
Read article →West Virginia has enacted prior authorization reform after Eric Tennant died following repeated denials of cancer treatment by the state's public employees insurer. His widow's advocacy directly influenced the legislation, which Governor Justice signed in March. The law represents a growing push to limit insurers' ability to override physician-recommended care.
Read article →Join thousands of readers who get the world's most important stories, curated daily.
Start reading free →